University of California San Francisco
Give to UCSF
Kathy Giacomini, PhD, who trained as a pharmacist and went on to become one of the foremost experts on pharmacogenomics with a focus on drug transporters, has been appointed dean of the UCSF School of Pharmacy.
In a study, UCSF neurologist William Seeley, MD, and colleagues identified two key moments in the natural history of Alzheimer’s, pointing to a window of opportunity for treatment with amyloid-lowering drugs.
55% of seniors with dementia take more than six medications even though most have good health. However, a UCSF study showed that 87% are willing to cut down if their doctors agree.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
A UCSF-led study found a new drug for ALS that shows to slow or temporarily stall the progression of ALS in a select group of patients, with three times as many patients' disease slowing compared to those who received a placebo.
For years, physicians have been taught to prescribe different drugs to Black people with high blood pressure. A recent UCSF study calls that into question.
In the quest for new treatments for COVID-19, a team led by UCSF researchers identified a new potential drug target that may prevent infection of human cells by SARS-CoV-2.
There is some information that is known about the variant and other information that sti
Americans save billions of dollars using lower-cost generics instead of brand-name drugs. Are they as effective?
A UCSF and Stanford study of electronic health records linked SSRIs, the most widely prescribed antidepressants, to survival for COVID-19 patients.
Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed.
A clinical trial of new treatment regimens, led in part by researchers at UCSF, recently demonstrated that a more potent combination of antibiotics could shorten the duration of treatment for TB.
